Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...

As our use of online tools expands wildly with the advent of artificial intelligence, so does the demand for data.

Discover why Southern Company offers 12% upside and a 3.5% yield. Explore Q3 results, growth from data centers, and dividend ...

The new international accounting standard is aimed at more consistent reporting that’s better aligned with how businesses are ...

A technology researcher says a wave of breakthroughs is accelerating faster than public awareness-and faster than U.S. infrastructure can handle.

A researcher calls for more interoperability, infrastructure expansion, and careful handling of patient data for the use of AI in healthcare.

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52)3/3 (100%) of ...

Photo from Freepik We make critical decisions that shape our company’s direction. Hiring. Training investments. Restructuring ...

Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera ...

Imperative Care, Inc. today announced the presentation of late-breaking, real-world data from a multi-center review of ischemic stroke patients treated with ADAPT 2.0, a next-generation approach to A ...